NF 449
目录号 : GC11326NF 449是一种高效的嘌呤能受体拮抗剂，对P2X1表现出高选择性（对于rP2X1、rP2X1+5、rP2X2+3和rP2X3受体，IC50值分别为0.28、0.69、120、1820nM）。
Cas No.:627034-85-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
NF 449 is an efficient purine receptor antagonist, showing high selectivity for P2X1 (IC50 values for rP2X1, rP2X1+5, rP2X2+3, and rP2X3 receptors are 0.28, 0.69, 120, and 1820nM, respectively) [1]. NF 449 is a Gsα-selective G protein antagonist that inhibits the rate of GTP [γS] binding to Gsα-s, inhibits the stimulation of adenylate cyclase activity, and blocks the coupling of β-adrenergic receptors with Gs [2]. NF 449 can be used to distinguish the effects mediated by P2X1 and P2X7 in natural tissues [3].
In vitro, NF 449 (10μM; 5min) treatment significantly inhibited the activation of Gαs and cAMP production in GLP-1 (7-36) amide-treated muscle cells, and blocked the increase in PKA activity [4]. NF 449 (2μM; 10min) pretreatment of multi-cellular preparations of HGOA almost completely inhibited the contraction response caused by 10μM αβ-meATP, with the average normalized peak contraction amplitude changing from 100±12% to 6±2% [5].
In vivo, NF 449 (10, 50mg/kg/day; i.v.) single treatment inhibited the P2X1 receptor in systemic thromboembolic model WT mice and reduced intravascular platelet aggregation, but did not prolong the bleeding time. At higher doses, NF 449 inhibited ex vivo platelet aggregation, inhibited three types of platelet P2 receptors, and further reduced platelet consumption [6]. NF 449 (10mg/kg; twice; i.v.) treatment significantly reduced the protein content of BAL in LPS-sensitized H-2d BALB/c mice, and at the same time, the area of interstitial small artery periphery edema in the mice also decreased [7].
References:
[1] Rettinger J, et al. Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF 449 as a highly potent P2X1 receptor antagonist. Neuropharmacology. 2005;48(3):461-468.
[2] Hohenegger M, et al. Gsalpha-selective G protein antagonists. Proc Natl Acad Sci U S A. 1998;95(1):346-351.
[3] Hülsmann M, et al. NF 449, a novel picomolar potency antagonist at human P2X1 receptors. Eur J Pharmacol. 2003;470(1-2):1-7.
[4] May AT, et al. Identification of expression and function of the glucagon-like peptide-1 receptor in colonic smooth muscle. Peptides. 2019; 112:48-55.
[5] Nichols CM, et al. Vascular smooth muscle cells from small human omental arteries express P2X1 and P2X4 receptor subunits. Purinergic Signal. 2014;10(4):565-572.
[6] Hechler B, et al. Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF 449 [4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid octasodium salt]. J Pharmacol Exp Ther. 2005;314(1):232-243.
[7] El Mdawar M B, et al. The ATP-gated P2X1 ion channel contributes to the severity of antibody-mediated transfusion-related acute lung injury in mice[J]. Scientific Reports, 2019, 9(1): 5159.
NF 449是一种高效的嘌呤能受体拮抗剂，对P2X1表现出高选择性（对于rP2X1、rP2X1+5、rP2X2+3和rP2X3受体，IC50值分别为0.28、0.69、120、1820nM）[1]。NF 449是一种Gsα选择性G蛋白(G Protein)拮抗剂，抑制GTP[γS]与Gsα-s结合的速率，抑制腺苷酸环化酶活性的刺激，阻断β-肾上腺素能受体与Gs的偶联 [2]。NF 449可用于区分天然组织中P2X1和P2X7介导的作用 [3]。。
在体外，NF 449（10μM; 5min）处理显著抑制GLP-1 (7-36)酰胺处理的肌细胞Gαs的激活和cAMP的产生，阻断了PKA活性的增加 [4]。NF 449（2μM; 10min）预处理HGOA 多细胞样本几乎完全抑制了由10μM αβ-meATP引起的收缩反应，平均归一化峰收缩幅度由100±12%变为6±2% [5]。
在体内，NF 449（10, 50mg/kg/day; i.v.）单次治疗在低剂量下抑制了系统性血栓栓塞模型WT小鼠P2X1受体并降低血管内血小板聚集，但并未延长出血时间。而在较高剂量下，NF 449抑制离体血小板聚集，NF 449抑制了三种血小板P2受体，血小板消耗进一步减少 [6]。NF 449（10mg/kg/d; twice; i.v.）治疗显著降低了LPS致敏的H-2d BALB/c小鼠动物中BAL的蛋白表达，同时小鼠的间质性小动脉周围水肿面积也减小[7]。
| Cell experiment [1]: | |
Cell lines | ESCC cells |
Preparation Method | Muscle cells in culture were treated with GLP-1(7–36) amide (1μM) for 5min in the presence or absence of Gαs activation inhibitor, NF 449 (10μM). In some experiments, muscle cells were treated with 1μM vasoactive intestinal peptide (VIP) for 5min. Isobutyl methyl xanthine (IBMX, 100μM) was used in the incubation to prevent cAMP hydrolysis. At the end of 5-minute incubation, medium was removed. Carry out the activation assay of Gαs and the concentration determination of cAMP. |
Reaction Conditions | 10μM; 5min |
Applications | The treatment with NF 449 significantly inhibited the activation of Gαs and the production of cAMP in the muscle cells treated with GLP-1 (7-36) amide, and blocked the increase in PKA activity. |
| Animal experiment [2]: | |
Animal models | Wild-type mice |
Preparation Method | The experiment utilized an acute systemic vascular thromboembolic model triggered by an injection of a mixture of collagen and epinephrine. Briefly, male mice weighing 25 to 30g were anesthetized and the jugular veins were exposed surgically. NF 449 or physiological saline was injected into the left jugular vein, 30s before injecting a mixture of 0.1mg/kg collagen and 60g/kg adrenaline that was injected within an infusion time frame of 3 to 4s into the right jugular vein. Two minutes later, blood was drawn from the abdominal aorta into 6mM EDTA anticoagulant, and platelets were counted in an ACT Coulter DiffTM counter. |
Dosage form | 10, 50mg/kg/day; Single-dose; i.v. |
Applications | At a low dose, NF 449 inhibited the P2X1 receptor and reduced intravascular platelet aggregation, but did not prolong the bleeding time. At a higher dose, NF 449 inhibited platelet aggregation in vitro, and NF 449 inhibited three types of platelet P2 receptors, resulting in further reduction in platelet consumption. |
References: | |
| Cas No. | 627034-85-9 | SDF | |
| 化学名 | sodium (1Z,3Z)-5-(((Z)-((3,5-bis((Z)-oxido((2-sulfo-4-sulfonatophenyl)imino)methyl)phenyl)imino)oxidomethyl)amino)-N'1-(2,4-disulfophenyl)-N'3-(2-sulfo-4-sulfonatophenyl)isophthalimidate | ||
| Canonical SMILES | [O-]/C(C1=CC(/C([O-])=N/C2=C(S(O)(=O)=O)C=C(S([O-])(=O)=O)C=C2)=CC(/N=C([O-])/NC3=CC(/C([O-])=N/C4=C(S(O)(=O)=O)C=C(S([O-])(=O)=O)C=C4)=CC(/C([O-])=N/C5=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C=C5)=C3)=C1)=N\C6=C(S(O)(=O)=O)C=C(S([O-])(=O)=O)C=C6.[Na+].[Na+].[Na+].[ | ||
| 分子式 | C41H24N6Na8O29S8 | 分子量 | 1505.06 |
| 溶解度 | PBS (pH 7.2): 10 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.6644 mL | 3.3221 mL | 6.6443 mL |
| 5 mM | 0.1329 mL | 0.6644 mL | 1.3289 mL |
| 10 mM | 0.0664 mL | 0.3322 mL | 0.6644 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet